199 related articles for article (PubMed ID: 17366800)
1. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
2. [Novel molecular approaches in the therapy of advanced colorectal carcinoma].
Vanhoefer U
Onkologie; 2003 Dec; 26 Suppl 7():70-4. PubMed ID: 14716146
[TBL] [Abstract][Full Text] [Related]
3. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
5. Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Normanno N; Tejpar S; Ciardiello F
J Natl Cancer Inst; 2010 Apr; 102(8):573; author reply 573-5. PubMed ID: 20305131
[No Abstract] [Full Text] [Related]
6. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
Jackson C; Cunningham D
Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
8. New treatment options for colorectal cancer.
Erlichman C; Sargent DJ
N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
[No Abstract] [Full Text] [Related]
9. A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
Taniguchi H; Komori A; Narita Y; Kadowaki S; Ura T; Andoh M; Yatabe Y; Komori K; Kimura K; Kinoshita T; Muro K
Jpn J Clin Oncol; 2016 Mar; 46(3):228-33. PubMed ID: 26759349
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
[TBL] [Abstract][Full Text] [Related]
11. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
Halama N; Herrmann C; Jaeger D; Herrmann T
Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
[TBL] [Abstract][Full Text] [Related]
12. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Saltz LB
Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
[No Abstract] [Full Text] [Related]
13. [Which role do new therapeutic options play in palliative care of colorectal cancer?].
Verbeek W; Graeven U
Internist (Berl); 2005 Dec; 46(12):1339-46. PubMed ID: 16228155
[TBL] [Abstract][Full Text] [Related]
14. Critical evaluation of current treatments in metastatic colorectal cancer.
Venook A
Oncologist; 2005 Apr; 10(4):250-61. PubMed ID: 15821245
[TBL] [Abstract][Full Text] [Related]
15. The role of targeted therapy in the treatment of colorectal cancer.
Goldberg RM; Hurwitz HI; Fuchs CS
Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241
[TBL] [Abstract][Full Text] [Related]
16. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
Vincenzi B; Santini D; Tonini G
J Clin Oncol; 2006 Apr; 24(12):1957; author reply 1957-8. PubMed ID: 16622275
[No Abstract] [Full Text] [Related]
17. New combinations in metastatic colorectal cancer: what are our expectations?
Hurwitz H
Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
[No Abstract] [Full Text] [Related]
18. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Mahtani RL; Macdonald JS
Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011
[TBL] [Abstract][Full Text] [Related]
19. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
Clin Colorectal Cancer; 2003 Aug; 3(2):85-8. PubMed ID: 12952562
[No Abstract] [Full Text] [Related]
20. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Köhne CH; Lenz HJ
Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
